12 Best Performing Healthcare Stocks to Buy Right Now

Page 2 of 10

9. Cidara Therapeutics, Inc. (NASDAQ:CDTX)

Number of Hedge Fund Holders: 34 

Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. Its lead candidate, CD388, is a long-acting antiviral designed to provide universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral replication.

In September 2025, CDTX gained momentum following an End-of-Phase 2 meeting with the FDA, announcing an accelerated and expanded Phase 3 trial for CD388. The study start has been moved up by six months to align with the fall flu season, and the participant pool now includes adults over 65, high-risk, and immunocompromised individuals aged 12 and older, effectively doubling the potential U.S. patient market to over 100 million. The FDA indicated that a single successful Phase 3 trial may suffice for biologics license application approval, streamlining CD388’s path to market.

Supporting this expansion, dosing began in September 2025 for the Phase 3 ANCHOR trial, enrolling 6,000 participants to prevent seasonal influenza in high-risk populations. Positive Phase 2b NAVIGATE study results and encouraging preclinical data against H5N1 influenza have further strengthened investor confidence, with analysts raising the company’s price targets up to $167. The stock recently surged over 19% amid strong market anticipation.

Beyond influenza, Cidara Therapeutics, Inc. (NASDAQ:CDTX) is advancing other DFC programs, including CBO421 for oncology, which targets CD73 in solid tumors and has received investigational new drug (IND) clearance. This diversification highlights the company’s growth potential across multiple therapeutic areas, positioning CDTX as a notable player in innovative biotech development.

Page 2 of 10